A5018576827- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Hormonal Regulation and Hypertension
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Cancer-related gene regulation
- Blood Pressure and Hypertension Studies
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Hemoglobinopathies and Related Disorders
- Antioxidant Activity and Oxidative Stress
- Adrenal and Paraganglionic Tumors
University Hospital Leipzig
2020-2024
National Center for Tumor Diseases
2021-2024
German Cancer Research Center
2010-2024
Heidelberg University
2015-2024
University Hospital Heidelberg
2010-2024
Heidelberg University
2024
University Medical Centre Mannheim
2023-2024
German Red Cross
2022-2024
Leipzig University
2021-2023
Radboud University Nijmegen
2012-2020
Purpose To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) 2 (IDH2) mutations in acute myeloid leukemia (AML). Patients Methods We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian Study Group (AMLSG) treatment trials HD98A APL HD95 for exon 4 IDH1 IDH2. were also NPM1, FLT3, MLL, CEBPA mutations. The median follow-up survival was 6.3 years. Results IDH found 129 patients (16.0%) —IDH1 61 (7.6%), IDH2 70 (8.7%). Two had both...
Abstract To evaluate internal tandem duplication (ITD) insertion sites and length as well their clinical impact in younger adult patients with FLT3-ITD–positive acute myeloid leukemia (AML), sequencing after DNA-based amplification was performed diagnostic samples from 241 FLT3-ITD–mutated patients. All were treated on 3 German-Austrian AML Study Group protocols. Thirty-four of the had more than 1 ITD, leading to a total 282 ITDs; median ITD 48 nucleotides (range, 15-180 nucleotides)....
PURPOSE The purpose of this study was to investigate frequency and prognostic significance high EVI1 expression in acute myeloid leukemia (AML). PATIENTS AND METHODS A diagnostic assay detecting multiple splice variants developed determine the relative by single real-time quantitative polymerase chain reaction 1,382 newly diagnosed adult patients with AML younger than 60 years. Patients were treated on four Dutch-Belgian HOVON (n = 458) two German-Austrian Study Group protocols 924). Results...
In a previous randomized trial, AML HD98B, we showed that administration of all-trans retinoic acid in addition to intensive chemotherapy improved the outcome older patients with acute myeloid leukemia. The objectives this study were evaluate prognostic impact gene mutations and identify predictive genetic factors for treatment effect.Data from mutation analyses NPM1, CEBPA, FLT3, MLL genes correlated 61 years treated within HD98B trial.The frequencies were: 23%; 8.5% (analysis restricted...
Summary Acute myeloid leukaemia ( AML ) with FLT3 mutation has a dismal prognosis in elderly patients. Treatment combination of FLT 3 inhibitors and standard chemotherapy not been extensively studied. Therefore, we instigated phase I/II clinical trial cytosine arabinoside (Ara‐C)/daunorubicin induction (7+3) followed by three cycles intermediate‐dose Ara‐C consolidation 22 patients activating mutations. Sunitinib was added at predefined dose levels as maintenance therapy for 2 years. At...
Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, many patients have benefited from its use. To date, six CAR products been approved by the FDA EMA, more are being developed investigated clinical trials. The whole field of adoptive transfer experienced an unbelievable development process, we now at edge new era immune therapies that will impact beyond hematologic malignancies. Areas interest are, e.g., solid...
Targeting constitutively activated FMS-like tyrosine kinase 3 [(FLT3); FLT3-ITD] with inhibitor (TKI) in acute myeloid leukemia (AML) leads to clearance of blasts the periphery but not bone marrow, suggesting a protective effect marrow niche on leukemic stem cells. In this study, we examined stromal cells CD34(+) progenitors from patients FLT3-ITD(+) or wild-type FLT3 (FLT3-WT) AML treated TKIs SU5614 sorafenib. effectively and specifically inhibited increased fraction undivided both FLT3-WT...
The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight had a FLT3-ITD (42%). Median age at 54.7 years, median follow-up for survival from time allografting 4.9 years. At transplantation, 31 were first, 20 second complete remission (CR) and 16...